By: IPP Bureau
Last updated : April 30, 2026 6:10 am
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
Becton, Dickinson and Company (BD) and Suttons Creek have announced a strategic, non-exclusive collaboration aimed at simplifying the complex engineering, testing, quality, and regulatory processes involved in combination product development.
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration. ZebraSci delivers objective, data-driven testing services that support decision-making across feasibility, performance, verification, and validation stages.
As pharmaceutical pipelines increasingly feature biologics, GLP-1 therapies, and other drug-device combinations, companies often encounter fragmented vendor ecosystems and disconnected workflows. This collaboration seeks to improve coordination across development stages while allowing customers to retain flexibility in selecting partners and technologies.
“Combination product development increasingly requires close coordination across strategy, testing, and delivery system considerations,” said Patrick Jeukenne, Worldwide President, BD Pharmaceutical Systems. “By bringing together complementary expertise, this collaboration helps reduce development risk and address regulatory requirements while maintaining flexibility.”
The joint model is designed to support biotech and pharma companies navigating compressed timelines and growing delivery complexities, particularly in biologics and GLP-1 segments. By addressing potential gaps earlier in development, it aims to create more predictable pathways and minimize late-stage rework.
“Combination product development spans multiple vendors and siloed workstreams, driving delays and regulatory risk,” said Carolyn Dorgan, Vice President of Solutions Engineering at Suttons Creek. “This collaboration enables a more coordinated and efficient path forward, helping reduce FDA data requests driven by misaligned strategies.”